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Introduction
Myeloid cells, most notably macrophages (Mø), regulate the 
inflammatory response to injury. Mø are integral in ischemia/
reperfusion injury–incited (I/R-incited) acute kidney injury 
(AKI) that resolves (1–3) or alternatively leads to chronic kidney 
disease (CKD) (3). As Mø mediate kidney repair and destruc-
tion, we reasoned that the principal molecule required for Mø 
survival, proliferation, and activation — CSF-1 — is central to 
regulating the fate of the kidney. Our prior studies show that 
CSF-1 expression is beneficial in kidneys destined to repair (4) 
and, conversely, harmful in kidneys destined for autoimmune-
mediated chronic disease (3, 5–8).
CSF-1 functions by engaging a high-affinity RTK encoded 
by the FMS proto-oncogene, the CSF-1R (c-FMS, also known 
as CD115) (9, 10). c-FMS is principally expressed on mono-
nuclear phagocytes, including progenitor cells (11), mono-
blasts, promonocytes, monocytes (12), Mø, and DCs (13). As 
FMS null mice developed a more severe phenotype than mice 
lacking CSF-1 (14), this finding led to the discovery of a second 
c-FMS ligand, IL-34.
IL-34 and CSF-1 have shared and differing properties. Both 
cytokines promote the growth and survival of monocytes and for-
mation of Mø colonies from BM (15). However, IL-34 is a dimeric 
glycoprotein without sequence homology to the secreted glyco-
protein CSF-1 isoform or any other known cytokine (16). More-
over, IL-34 and CSF-1 differ in spatiotemporal expression in some 
adult and developing tissues (15), and they have partially overlap-
ping c-FMS binding domains that may be responsible for dissim-
ilar signal-activation kinetics (17). IL-34, but not CSF-1, is critical 
in the maintenance of tissue-resident homeostatic Mø, such as 
Langerhans cells and microglia (18). Moreover, while both IL-34 
and CSF-1 signal through c-FMS, IL-34 has a second recently 
uncovered receptor, PTP-ζ, at least in the brain (19). Although 
CSF-1–mediated mechanisms during renal inflammation are well 
documented by our laboratory and others (3, 5, 7, 8, 20–25), the 
role of IL-34 in inflammation, particularly in the kidney, has not 
been explored. The central issues are: (i) do IL-34–dependent, 
Mø-mediated mechanisms augment or thwart AKI and subse-
quent CKD; (ii) are CSF-1 and IL-34 redundant during renal injury; 
(iii) do IL-34–dependent, Mø-mediated mechanisms within and/
or outside the kidney alter renal injury; (iv) are IL-34–dependent 
mechanisms responsible for shifting the dominant intrarenal Mø 
phenotype prior to and/or after I/R; and (v) is intrarenal and sys-
temic IL-34 expression relevant to ischemia-incited human AKI 
and subsequent CKD? Taken together, we tested the hypothesis 
that IL-34–dependent, Mø-mediated mechanisms promote per-
sistent ischemia-incited AKI and the subsequent CKD.
Macrophages (Mø) are integral in ischemia/reperfusion injury–incited (I/R-incited) acute kidney injury (AKI) that leads to 
fibrosis and chronic kidney disease (CKD). IL-34 and CSF-1 share a receptor (c-FMS), and both cytokines mediate Mø survival 
and proliferation but also have distinct features. CSF-1 is central to kidney repair and destruction. We tested the hypothesis 
that IL-34–dependent, Mø-mediated mechanisms promote persistent ischemia-incited AKI that worsens subsequent CKD. 
In renal I/R, the time-related magnitude of Mø-mediated AKI and subsequent CKD were markedly reduced in IL-34–deficient 
mice compared with controls. IL-34, c-FMS, and a second IL-34 receptor, protein-tyrosine phosphatase ζ (PTP-ζ) were 
upregulated in the kidney after I/R. IL-34 was generated by tubular epithelial cells (TECs) and promoted Mø-mediated TEC 
destruction during AKI that worsened subsequent CKD via 2 distinct mechanisms: enhanced intrarenal Mø proliferation and 
elevated BM myeloid cell proliferation, which increases circulating monocytes that are drawn into the kidney by chemokines. 
CSF-1 expression in TECs did not compensate for IL-34 deficiency. In patients, kidney transplants subject to I/R expressed 
IL-34, c-FMS, and PTP−ζ in TECs during AKI that increased with advancing injury. Moreover, IL-34 expression increased, 
along with more enduring ischemia in donor kidneys. In conclusion, IL-34-dependent, Mø-mediated, CSF-1 nonredundant 
mechanisms promote persistent ischemia-incited AKI that worsens subsequent CKD. 
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ure 1D). By comparison, intrarenal Il34 transcripts and protein are 
barely expressed prior to I/R (Figure 1, B and C). Il34–/– kidneys 
served as negative controls (Figure 1, B and C). Thus, IL-34 and 
CSF-1 expression is abundant in renal tubules, but not necessarily 
the same TECs, after I/R.
Overlapping and distinct expression of intrarenal IL-34 recep-
tors after I/R. IL-34 and CSF-1 are ligands for c-FMS, a receptor 
expressed on Mø and some other hematopoietic and parenchy-
mal cells. However, unlike CSF-1, IL-34 binds to a second func-
tional receptor, PTP-ζ, recently identified in mouse brain. We 
examined the temporal response of Fms and Ptprz1 after I/R 
using quantitative PCR (qPCR). Intrarenal Fms is expressed in 
the acute phase (d3, d5) and increases during the chronic phase 
(d20) after I/R (Figure 2A). We now report the finding that PTP-ζ 
transcripts (Figure 2B) and protein (Figure 2C) are expressed 
in the inflamed mouse kidney, albeit less robustly than in brain 
(data not shown). Moreover, ischemia-induced IL-34 binds to 
PTP-ζ in the kidney at d20 after I/R (Figure 2D). By compari-
son, Fms is more abundantly expressed than Ptprz1 during AKI, 
while both are robustly increased during the chronic phase 
after I/R (Figure 2, A and B). Using immunostaining, we found 
PTP-ζ is expressed primarily by TECs and, to a lesser extent, by 
cells in the inflamed interstitium after I/R (Supplemental Fig-
ure 1A; supplemental material available online with this article; 
doi:10.1172/JCI81166DS1). We verified staining specificity using 
an isotype control and by titration analysis. To further verify that 
PTP-ζ is expressed by TECs, we stimulated primary cultured 
Results
Renal ischemic injury incites robust expression of IL-34 and CSF-1 in 
tubules. Tubules, most notably in the outer medulla, are sensitive 
to ischemic injury (26). Moreover, the interstitial areas adjacent to 
ischemic-injured tubules are rich in Mø that often surround and 
adhere to tubular epithelial cells (TECs) (3). Since IL-34 binds 
to receptors on Mø and promotes Mø proliferation, we hypothe-
sized that IL-34 is expressed by tubules following ischemic injury. 
To test this hypothesis, we probed for the locale and magnitude 
of IL-34 expression in the renal medulla and cortex of B6 mice 
prior to and after I/R. Using in situ hybridization, we localized 
ischemia-incited IL-34 expression to tubules (proximal, distal, 
and collecting ducts) (Figure 1A). We verified this finding using 
heterozygous IL-34–knockin mice (Il34LacZ/+) in which the IL-34 
coding region was replaced by the gene coding β-galactosidase 
(data not shown) (18). By comparison, CSF-1 — evaluated using 
CSF-1 reporter mice expressing β-galactosidase — and IL-34 are 
similarly expressed, as both c-FMS ligands are more abundant 
in the medulla than in the cortex after I/R (Figure 1A). However, 
while some TECs express both IL-34 and CSF-1 protein (immu-
nostaining), other adjacent TECs express either IL-34 or CSF-1 
in inflamed human kidneys (lupus nephritis, data not shown). 
Moreover, IL-34 transcripts (Figure 1B) and protein (Figure 1C) 
are robustly expressed after I/R. IL-34 expression rises rapidly 
during the acute phase (d3, d5) and remains elevated during the 
chronic phase (d20) (Figure 1, B and C) after I/R. As above, Il34 
transcripts are more pronounced in the medulla than cortex (Fig-
Figure 1. IL-34 is increased in the kidney after I/R. In each figure, expression is analyzed before and after I/R. (A) IL-34 expression in B6 TECs identified 
using in situ hybridization (ISH), and CSF-1 using a CSF-1 reporter mouse (lacZ under control of Csf1 promoter and first intron) stained for β-galactosidase 
activity (X-gal). Representative photomicrographs (n = 5). Original magnification, ×2.5; inset, ×20. Dotted lines indicate the junction between the cortex (C) 
and the medulla (M). (B and C) We detected expression of intrarenal IL-34 transcripts and protein using qPCR (n = 5/group) (B) and ELISA (n = 4–11/group) 
(C), respectively. (D) Il34 transcripts in the cortex and medulla were evaluated using qPCR (n = 5/group). *P < 0.01, **P < 0.001. Statistics analyzed using 
the Mann-Whitney U test. Values are means ± SEM.
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injury molecule 1 (KIM-1) in WT and Il34–/– mice after I/R. KIM-1 
protein (Figure 4A) and transcripts (data not shown) are more 
robustly expressed in WT compared with Il34–/– TECs during 
the acute phase after I/R. This suggests that IL-34 expression is 
central to the initiation of tubule injury. Consistent with IL-34 
driving AKI that is reflected in subsequent CKD, serum levels 
of neutrophil gelatinase–associated lipocalin (NGAL), a reliable 
marker of AKI progressing to CKD (27) (Figure 4B), and albu-
minuria (Figure 4C) are higher in WT compared with Il34–/– mice 
at d3 and d20 after I/R. Moreover, we detected more renal fibro-
sis in WT compared with Il34–/– mice during the chronic phase 
after I/R. Collagen protein was detected using Picrosirius red 
staining (Figure 4D), and collagen 1 transcripts were detected 
using qPCR (data not shown). Thus, ischemia-incited IL-34 
mediates leukocyte-rich inflammation and tubule injury during 
AKI and subsequent worsening of CKD.
IL-34 promotes intrarenal myeloid cell accumulation after renal 
ischemic injury. Because myeloid cells, and in particular Mø, 
are integral to renal ischemic injury and repair (3), we hypoth-
esized that IL-34 promotes myeloid-mediated renal injury. As 
anticipated, the accumulation of intrarenal neutrophils (Ly6G+) 
precedes Mø (F4/80+), and declines rapidly as Mø ascend 
and remain prominent in WT mice after I/R (Figure 5A). We 
detected more intrarenal neutrophils and Mø in WT compared 
with Il34–/– during the acute and chronic phase after I/R (Figure 
5A). Consistent with the enhanced magnitude of IL-34 expres-
sion, neutrophil and Mø accumulation was more abundant in 
the medulla than cortex (Figure 5A). To identify the intrarenal 
leukocyte populations in ischemia-incited renal injury, we used 
flow cytometry (Figure 5B). We verified that fewer intrarenal 
myeloid cells (CD45+CD11b+) are in Il34–/– compared with WT 
TECs with either TNFα or IL-34 and analyzed Ptprz1 expression 
using qPCR. Ptprz1 transcripts are upregulated in response to 
either stimulus (Supplemental Figure 1B). While Mø ubiquitously 
expressed c-FMS, it is unlikely that intrarenal Mø express PTP-ζ, 
as WT BM-derived Mø (BMMø) polarized toward M1 and M2 
phenotypes, representing opposite ends of the activation spec-
trum, do not express PTP-ζ in vitro. (Supplemental Figure 1C). 
Thus, intrarenal c-FMS and PTP-ζ have overlapping and distinct 
expression after I/R.
IL-34 mediates loss of tubules evident by the chronic phase after 
I/R. To determine if IL-34 is central to promoting renal disease, 
we compared pathology in Il34–/– and WT mice in AKI and subse-
quent CKD after I/R (Figure 3A). Kidney weight and size is more 
dramatically decreased in WT mice compared with Il34–/– mice 
at d20 and d37 after I/R (Figure 3B). As escalating inflammation 
drives renal injury, we hypothesized that ischemia-incited renal 
tubule IL-34 expression promotes leukocyte accumulation in the 
interstitium, leading to tubule destruction. We detected more 
tubular pathology (atrophy) and leukocytes in the interstitium in 
WT compared with Il34–/– mice after I/R (Figure 3C). To more fully 
compare the loss of tubules in Il34–/– and WT mice after I/R, we 
used lotus tetragonolobus lectin (LTL) to detect proximal tubules 
and dolichos biflorus agglutinin (DBA) to detect collecting ducts. 
By the chronic phase after I/R, there are far fewer LTL+ and DBA+ 
cells in WT compared with Il34–/– kidneys (d37, Figure 3D). Similar 
findings appeared at d20 (data not shown). Thus, ischemia-incited 
IL-34–dependent mechanisms mediate loss of tubules evident 
during the chronic phase after I/R.
IL-34 mediates tubular injury during AKI. To determine 
if intrarenal IL-34 fosters acute tubule injury leading to the 
chronic loss of tubules, we compared the expression of kidney 
Figure 2. IL-34 receptors have 
overlapping and distinct 
expression in the kidney after 
I/R and IL-34 binds to PTP-ζ. 
(A–B) Intrarenal Fms (A) and 
Ptprz1 (B) transcript expression 
on the same samples using 
qPCR (repeated 3×). Statistics 
analyzed using the Mann-Whit-
ney U test. *P ≤ 0.05, **P ≤ 0.01. 
Values are means ± SEM. (C). 
Intrarenal PTP-ζ protein levels 
detected by immunoblotting. 
Quantitation of PTP-ζ relative 
to GAPDH (n = 4). Statistics 
analyzed using unpaired t test 
(Mann-Whitney U test).  
*P < 0.03. Values are means ± 
SEM. (D) Immunoprecipitation 
performed from kidney lysates 
with PTP-ζ or control (mouse 
IgG) Ab showing IL-34 binding  
to PTP-ζ (n = 3).
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To determine if IL-34 generated from ischemic TECs directly 
fosters Mø proliferation, we used several in vitro approaches. We 
compared Mø (WT BMMø) proliferation after stimulation with 
supernatant from primary cultured hypoxic Il34–/– and WT TECs 
(Figure 7A). We detected greater Mø proliferation after stimula-
tion with hypoxic WT compared with Il34–/– TEC supernatants, as 
assessed by the MTT assay (Figure 7B). Therefore, hypoxia-incited 
IL-34 expression by TECs enhances Mø proliferation. Mø stimu-
lated with media alone or containing 20% L929 supernatant plus 
10% FCS served as negative and positive controls, respectively. 
Note, we did not detect a difference in viability of hypoxic WT and 
Il34–/– TECs or normoxic WT and Il34–/– TECs, using trypan blue 
exclusion and propidium iodide (PI) staining (Supplemental Fig-
ure 2A). Thus, Mø-stimulating supernatants are generated from 
equivalent numbers of TECs. As the MTT assay is an index of both 
proliferation and viability, to verify our proliferation findings, we 
repeated the above experiment using BrdU incorporation in place 
of MTT. Similarly, the number of BrdU+ Mø rises after stimula-
tion with hypoxic compared with normoxic WT TEC supernatant 
(Supplemental Figure 2B). Moreover, decreasing the concentration 
of hypoxic supernatant reduces the magnitude of BrdU+ Mø (Sup-
plemental Figure 2B). We verified that IL-34 in TEC supernatant 
enhances Mø proliferation by adding recombinant IL-34 (rIL-34) to 
the stimulating hypoxic Il34–/– TEC supernatant. Adding increasing 
mice after I/R (Figure 5C). The decline in intrarenal myeloid 
cells in Il34–/– mice is initially due to a reduction in neutrophils 
(CD45+Ly6G+CD11b+) (Figure 5D) and later results from fewer 
Mø (CD45+CD11b+Ly6G–F4/80+) (Figure 5E). Thus, ischemia- 
incited IL-34 expression mediates neutrophil and Mø accumu-
lation in inflamed kidneys.
Renal ischemia incites IL-34 expression that promotes intrarenal 
Mø proliferation. Mø, but not neutrophils, express the CSF-1 and 
IL-34 receptor (c-FMS). Thus, signaling through c-FMS on Mø 
may be responsible for intrarenal Mø accumulation after I/R. We 
tested the hypothesis that ischemia-incited IL-34 expression in 
TEC promotes intrarenal Mø proliferation. To test this hypothe-
sis, we used 2 complementary in vivo proliferation assays: in situ 
immunostaining (Ki67) and flow cytometry (5′-Bromo-2-deoxy-
uridine [BrdU]). We detected more intrarenal proliferating Mø 
(Ki67+F4/80+ cells) in WT compared with Il34–/– mice during the 
acute phase (d3, d5) and chronic phase (d20) after I/R (Figure 
6A). Similarly, intrarenal BrdU+ myeloid cells (CD45+CD11b+), 
and more specifically Mø (CD45+CD11b+Ly6G–), are far more 
abundant in WT compared with Il34–/– mice during the acute and 
chronic phases after I/R (Figure 6B). The frequency of BrdU+ 
neutrophils remained low throughout the experiment (data not 
shown). Thus, ischemia-incited IL-34 expression drives intrarenal 
Mø proliferation.
Figure 3. Tubular atrophy and interstitial infiltration are diminished in Il34–/– after I/R. (A) Scheme: Time-related comparison for AKI and CKD after I/R. 
(B) Representative kidneys from Il34–/– and WT B6 mice (left panel) and change in kidney weights (contralateral minus I/R kidney; right panel) after I/R  
(n = 4–6/group). (C) Graphs indicate tubular atrophy and interstitial infiltration grades after I/R injury. Representative photomicrographs after I/R. Original 
magnification, ×40. T, Tubule (n = 6–8/group). (D) LTL identifies proximal tubules, and DBA identifies collecting ducts after I/R. Graphs and representative 
photomicrographs after I/R. Original magnification, ×10 (n = 6/group). Statistics analyzed using the Mann-Whitney U test. *P < 0.05,  
**P < 0.01. Values are means ± SEM.
Downloaded from http://www.jci.org on December 11, 2015.   http://dx.doi.org/10.1172/JCI81166
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
3 2 0 2 jci.org   Volume 125   Number 8   August 2015
an elevation of circulating IL-34 after I/R (Figure 8A). Moreover, 
IL-34 contributes to myeloid cell development and thereby may 
increase circulating monocytes (15). Therefore, we tested the 
hypothesis that elevated systemic IL-34 increases the number of 
circulating myeloid cells that are recruited to the kidney. Using 
flow cytometry (Figure 8B), we detected an increase in myeloid 
cells (Figure 8C), neutrophils (Ly6G+Ly6Cint, Figure 8D), and 
inflammatory/migratory monocytes (CD45+CD11b+Ly6G–Ly6Chi, 
Figure 8E) in circulation during the acute phase after I/R. Thus, 
IL-34 promotes an increase of circulating neutrophils and mono-
cytes during ischemia-incited AKI.
To determine whether systemic IL-34 promotes the rise in cir-
culating myeloid cells, we tested the hypothesis that IL-34 medi-
ates myeloid cell proliferation in the BM that subsequently enters 
the circulation. To test this hypothesis, we analyzed myeloid cell 
BrdU incorporation in BM, blood, and kidney before and after I/R 
(Figure 8F). BrdU+ BM myeloid progenitor cells (SSCloCD45+CD-
11b+Ly6G–) are increased in WT compared with Il34–/– mice during 
the acute phase after I/R (Figure 8F, BM). Moreover, we detected 
elevated circulating BrdU+ myeloid cells in WT compared with 
Il34–/– BM during the acute phase after I/R (Figure 8F, Circulation, 
left). The increase in circulating myeloid cells results from a rise in 
both neutrophils (Figure 8F, Circulation, middle) and monocytes 
(Figure 8F, Circulation, right) in WT compared with Il34–/– mice. 
Thus, IL-34 promotes BM myeloid progenitor proliferation, lead-
ing to a rise of circulating monocytes and neutrophils after I/R.
To explore whether a rise in myeloid cells in the circulation 
leads to a greater abundance of myeloid cells in the kidney, we 
adoptively transferred equal numbers of CSF-1 receptor–labeled 
BM cells (eGFP+ BM cells) into Il34–/– and WT mice (3 hours prior 
concentrations of rIL-34 restores Mø proliferation, in a step-wise 
manner, to WT levels and beyond (MTT assay, Figure 7C). Thus, 
IL-34 released from hypoxic TEC directly induces Mø proliferation.
Are IL-34 and CSF-1 released into the supernatant of hypoxic 
TECs both responsible for driving Mø proliferation? IL-34 and 
CSF-1 (protein) are upregulated in the supernatant of hypoxic WT 
TEC (Figure 7E). Anti–IL-34 (neutralizing) Ab blockade of IL-34 in 
supernatants from hypoxic WT TECs partially reduces Mø prolif-
eration (Figure 7D). Similarly, substituting anti–CSF-1 Ab in place 
of anti–IL-34 Ab also partially reduces Mø proliferation. More-
over, Mø proliferation is reduced to baseline (media alone) levels 
by blocking CSF-1 in Il34–/– hypoxic TEC supernatants (Figure 7D) 
and by blocking CSF-1 together with IL-34 (using increasing con-
centrations of Abs) in WT hypoxic TEC supernatants (Supplemen-
tal Figure 2C). Thus, hypoxic TEC release IL-34 and CSF-1, which 
additively are responsible for driving Mø proliferation.
Does CSF-1 compensate for the absence of IL-34 in the 
ischemic kidney? We found that CSF-1 protein does not increase 
in the supernatant of either hypoxic or TNFα-stimulated Il34–/– 
compared with WT TECs (Figure 7F). We found similar results 
analyzing CSF-1 protein in TNFα-stimulated TEC homogenates 
from Il34–/– compared with WT mice (data not shown). This is 
consistent with equivalent expression of Csf1 transcripts in TNFα-
stimulated Il34–/– compared with WT TECs (Supplemental Figure 
2D). Thus, CSF-1 does not compensate for the absence of IL-34 in 
ischemic-injured TECs.
IL-34 stimulates BM myeloid cell proliferation and elevates circu-
lating myeloid cells that are recruited to the kidney after I/R. Intrare-
nal IL-34 proliferation alone may not account for all IL-34–depen-
dent Mø accumulation in the kidney. In this regard, we detected 
Figure 4. KIM-1 expression and intrarenal fibrosis are decreased in Il34–/– after I/R. (A) KIM-1 expression (red) immunofluorescence after I/R. Graphs 
(KIM-1/HPF) and representative photomicrographs. Nuclei are stained with DAPI (blue). Original magnification, ×20 (n = 6–8/group). (B) Serum NGAL lev-
els evaluated by Luminex technology. (C) Urine albumin excretion over 8 hours evaluated by SDS-PAGE after I/R (n = 3–17/group). (D) Renal fibrosis using 
collagen staining (Picrosirius red). Graphs (% Picrosirius red) and representative photomicrographs after I/R. Original magnification, ×10 (n = 6–8/group). 
Statistics analyzed using the Mann-Whitney U test. *P < 0.05, **P < 0.01. Values are means ± SEM.
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to sacrifice) after I/R. We found similar eGFP+ BM cells in the 
circulation, but we found more eGFP+ cells in the kidney in WT 
than Il34–/– mice (Figure 9A). Thus, IL-34 mediates the number of 
eGFP+ (myeloid cells) recruited to the inflamed kidney. Moreover, 
we followed the same protocol but injected half the number of 
eGFP-labeled BM cells into Il34–/– mice. We found that the num-
ber of labeled cells injected into the circulation is proportional to 
the number in the kidney (Figure 9A). Thus, increasing myeloid 
cells in the circulation leads to more myeloid cell trafficking into 
the inflamed kidney.
IL-34 mediates a rise in intrarenal chemokines that recruit mono-
cytes to the inflamed kidney. Is IL-34 directly or indirectly respon-
sible for enhancing monocyte recruitment to the kidney? To test 
whether IL-34 directly recruits myeloid cells, we used a transwell 
system; the upper and lower chambers are separated by a porous 
membrane (Figure 9B). We determined whether stimulated TECs 
expressing IL-34 (lower chamber) recruits WT BMMø (upper cham-
ber). To avoid IL-34–mediated Mø proliferation (18- to 22-hour 
turnover rate) (28), we examined recruitment at 3 hours and 6 
hours after BMMø are seeded into the upper chamber. Blocking 
Figure 5. Fewer Mø and neu-
trophils in Il34–/– compared 
with WT kidneys after I/R. (A) 
Neutrophils (Ly6G+/HPF) and 
Mø (F4/80+/HPF) in the cortex 
and medulla identified using 
immunostaining. Representative 
photomicrographs. Original mag-
nification, ×10 (n = 4–6/group). 
(B) Scheme depicting cell-sorting 
approach. (C–E) Myeloid cell 
(C), neutrophil (D), and Mø (E) 
analysis by flow cytometry from 
the whole kidney (n = 4–6/group). 
Graphs and representative plots. 
Statistics analyzed using the 
Mann-Whitney U test. *P < 0.05, 
**P < 0.01, ***P < 0.001. Values 
are means ± SEM.
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MCP-1, a well-established Mø chemoattractant, reduced BMMø 
migration at 6 hours (Figure 9B) and 3 hours (data not shown) after 
BMMø are seeded into the upper chamber in a dose-responsive 
manner. In contrast, blocking IL-34 did not alter BMMø migration 
at 6 hours (Figure 9B) and 3 hours (data not shown) using the same 
dose range as for MCP-1. This suggests that IL-34 generated by 
TECs is not directly responsible for Mø recruitment.
We next tested the hypothesis that IL-34 indirectly recruits mye-
loid cells by increasing intrarenal chemokines. We detected more 
intrarenal chemokines (MCP-1, also known as CCL2; MIP-1α, also 
known as CCL3; and CX3CL1, also known as fractalkine), known 
to recruit Mø, in WT compared with Il34–/– after I/R (Figure 10A). 
The elevation in chemokines is not limited to those recruiting Mø, as 
intrarenal IP-10, also known as CXCL10, (recruits T cells) is increased 
and T cells are more abundant in WT compared with Il34–/– mice at d5 
and d20 after I/R (Figure 10A and Supplemental Figure 3).
To determine whether IL-34 directly stimulates intrarenal 
chemokine expression, we stimulated TECs with mouse IL-34 in 
vitro. Stimulating TEC with TNFα (25 ng/ml) readily amplifies 
chemokine expression (Figure 10B). In contrast, stimulating TECs 
with varying doses of IL-34 (up to 10 times more than TNFα) does 
not induce chemokine expression (Figure 10B). This suggests that 
IL-34 does not directly induce chemokine expression in TECs.
To determine whether chemokines are primarily responsible 
for recruiting Mø into the inflamed kidney, we blocked G protein–
coupled signaling, which blocks chemokine receptors, in BM cells 
from MacGreen mice (eGFP reporter for c-FMS). For this purpose, 
we incubated MacGreen BM cells with pertussis toxin (PTx) prior 
to injecting these cells into WT mice after I/R (d1) (Figure 10C). 
MacGreen BM cells incubated with heat-inactivated PTx served 
as a negative control. The viability of MacGreen BM cells treated 
with PTx or heat-inactivated PTx is 98 %–99% (PI staining, data 
not shown). Blocking G protein–coupled signaling in eGFP+ WT 
BM cells nearly eliminates all recruitment of these cells into the 
inflamed kidney (Figure 10C). Taken together, IL-34 mediates 
the proliferation of BM cells that, in turn, enter the circulation, 
thereby increasing circulating myeloid cells that are recruited to 
the inflamed kidney. Moreover, our data suggest that IL-34 indi-
rectly mediates a rise in intrarenal chemokines that recruits mye-
loid cells into the kidney after I/R. In conclusion, both intrarenal 
and systemic mechanisms regulate IL-34–dependent accumula-
tion of myeloid cells in the inflamed kidney.
The processes of maintaining kidney-resident Mø and skewing 
intrarenal-incited Mø phenotypes after ischemia are not dependent on 
IL-34. Tissue-resident Mø (Ly6C–) are seeded during early devel-
opment and maintained locally through homeostatic proliferation, 
independent of monocytes. By comparison, Mø (Ly6C+) derived 
from monocytes are recruited into inflamed tissues, where they 
multiply and exert cyto-destructive or cyto-protective functions 
(28). Recent studies indicate that IL-34 is required to maintain 
homeostatic cyto-protective tissue-resident Mø (Ly6C–) in some 
tissues, such as the brain and skin (18, 29). Thus, we determined 
Figure 6. IL-34 expressed by TECs promotes Mø proliferation. In vivo Mø Proliferation: (A) Paraffin sections dual-stained with anti-Ki67 (red) and 
anti-F4/80 (green) Ab to identify proliferating Mø after I/R (n = 4–10/group). Dashed white lines outline tubules, and white arrows indicate Ki67-positive 
nuclei. Representative photomicrographs and corresponding graphs (Ki67+F4/80+ cells/HPF). Original magnification, ×20. (B) Proliferating myeloid cells 
and Mø are identified by BrdU staining and analyzed using flow cytometry (n = 3–6/group). Statistics analyzed using the Mann-Whitney U test. *P < 0.05, 
**P < 0.01, ***P < 0.001, #P < 0.07, †P < 0.09. Values are means ± SEM.
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Broadly, Mø responding to local signals are divided into 
functional states at opposite ends of the activation spectrum 
(referred to as M1 and M2). Simplistically, M1 Mø promote 
injury, while M2 are reparative (30–32). We tested the hypoth-
esis that an IL-34–dependent shift in Mø phenotypes promotes 
AKI. We found a predominance of M1-like Mø (CD45+Ly6G–
F4/80+NOS-2+TNFα+) during the acute phase that shift to the 
M2 (CD45+Ly6G–F4/80+Arginase-1+Dectin-1+CD206+) phe-
notype during the chronic phase in WT mice after I/R (Sup-
plemental Figure 5). The predominance of M1-like Mø during 
the acute phase and M2-like Mø (CD45+Ly6G–F4/80+Argi-
nase-1+Dectin-1+CD206+) during the chronic phase is more 
pronounced in WT compared with Il34–/– mice. However, 
IL-34 does not skew intrarenal Mø toward either an M1-like or 
M2-like phenotype, as the frequency of these phenotypes are 
similar in WT and Il34–/– mice after I/R (Supplemental Figure 5). 
Thus, IL-34 expression does not shift intrarenal Mø phenotypes 
toward either an M1 or M2 phenotype, but rather expands the 
accumulation of Mø phenotypes.
whether IL-34 is required for the maintenance of tissue-resident 
Mø in the kidney. We detected equivalent numbers of Ly6C– Mø 
(CD45+Ly6C–CD11b+Ly6G–F4/80+) in Il34–/– compared with WT 
kidneys (nonmanipulated) (Supplemental Figure 4C) and in the 
circulation (Supplemental Figure 4B). Moreover, the absence of 
IL-34 does not alter kidney development, as Il34–/– and WT kid-
neys are the same size (kidney/body weight, Supplemental Figure 
4A) and appear similar by histology (data not shown). Thus, IL-34 
is not required for kidney-resident Mø homeostasis. Once in the 
inflamed kidney, Ly6C– Mø may either reflect an expansion of tis-
sue-resident Mø or invading monocytes that switch from Ly6C+ to 
Ly6C–. We detect equivalent frequencies of Ly6C– and Ly6C+ Mø 
in WT and Il34–/– kidneys, and we detect more Ly6C+ and Ly6C– 
Mø in WT compared with Il34–/– kidneys after I/R (Supplemental 
Figure 4). While there are far more Ly6C– than Ly6C+ Mø in both 
WT and Il34–/– kidneys, it remains unclear whether this reflects 
an expansion of tissue-resident or invading monocytes. Taken 
together, IL-34 expression does not skew Mø toward either Ly6C+ 
or Ly6C– phenotype in the kidney prior to or after I/R.
Figure 7. IL-34 generated from hypoxic TECs directly induces Mø proliferation. In vitro Mø proliferation: (A) Scheme. (B) Cultured WT BMMø stimulated 
(24 hours) with supernatants of Il34–/– and WT TECs after hypoxia or normoxic (24 hours) (MTT assay) (n = 3–4/group). (C) To rescue IL-34 in Il34–/– TEC 
supernatant, rIL-34 is added to TEC supernatant prior to stimulating WT BMMø (MTT assay) (n = 3/group). (D) To block IL-34 or CSF-1 in WT TEC superna-
tant, anti–IL-34 or anti–CSF-1 Ab, respectively, are added to the TEC supernatant prior to stimulating WT BMMø (n = 3–4/group). (E) IL-34 and CSF-1 pro-
tein in supernatant of hypoxic and normoxic (24 hours) TECs evaluated by ELISA (n = 3-5/group). Dotted line represents Il34–/– hypoxic supernatant control 
(n = 2). (F) CSF-1 protein in the supernatant of TNFα (25 ng/ml) stimulated and hypoxic Il34–/– and WT TECs. CSF-1 control is serum from mice injected i.p. 
with LPS (25 μg) (n = 3–5/group). Statistics analyzed using the Mann-Whitney U test. *P ≤ 0.05, **P < 0.01. Values are means ± SEM.
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and deceased after reperfusion) and rises even higher during 
acute kidney rejection (Figure 11A). In mice, after I/R, IL-34 is 
expressed predominately by TECs (Figure 1A), and IL-34 medi-
ates the survival and proliferation of Mø and the accumulation of 
neutrophils. Therefore, we tested the hypothesis that intrarenal 
IL-34 expression promotes the accumulation of intrarenal mye-
loid cells. Consistent with the level of IL-34 expression in TECs, 
we detected far more Mø (CD68+) and neutrophils (Ly6G+) in 
IL-34 and IL-34 receptors are upregulated in TECs after I/R in 
human kidneys. IL-34 is upregulated in ischemia-incited human 
inflamed kidneys. Because I/R injury is an inevitable consequence 
of the kidney transplant procedure and prolonged ischemia leads 
to poorer graft survival (33), we probed for IL-34 in the engrafted 
and rejected kidney during the first 6 months after transplanta-
tion (acute phase) (Supplemental Table 1A). IL-34 is upregulated 
in the engrafted kidney compared with the donor kidney (living 
Figure 8. IL-34 promotes myeloid cell proliferation in BM and increases circulating monocyte. (A) IL-34 protein in the circulation of WT mice after I/R 
measured using an ELISA (n = 3–6/group). The serum collected 6 hours after LPS injection (25 μg, i.p.) into WT mice is used as a positive control, and 
serum from Il34–/– mice (dashed line) is used as a negative control (n = 14). (B–E) Scheme (B), graphs, and plots using flow cytometry analysis to evaluate 
the frequency of myeloid cells (C), neutrophils (D), and monocytes (E) in the circulation after I/R (n = 4–10/group). (F) Scheme. BrdU (2 mg) was injected 3 
hours prior to sacrifice. Data was analyzed using flow cytometry. BM: Proliferating SSClo myeloid cells in BM. Circulation: Proliferating circulating myeloid 
cells, Ly6Chi neutrophils and monocytes mice (n = 3–6/group). Statistics analyzed using Mann-Whitney U test. *P < 0.05, **P < 0.01, #P ≤ 0.06, †P < 0.09. 
Values are means ± SEM.
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dant in the chronic compared with acute phase after I/R, we com-
pared PTP-ζ in patients with acute and chronic kidney transplant 
rejection. Similar to our findings in mice, PTP-ζ is more abundant 
in chronic compared with acute kidney transplant rejection (Fig-
ure 12B). Since IL-34 and IL-34–receptor expression in mouse and 
human kidneys are similarly upregulated within ischemia-incited 
renal injury, and IL-34 promotes ischemia-incited AKI, we specu-
late that IL-34 mediates human renal injury.
Discussion
We report here the finding that IL-34 promotes Mø-mediated 
persistent ischemia-incited AKI, worsening subsequent CKD. 
IL-34 expression is upregulated in TECs during the acute phase 
and remains elevated during the chronic phase after I/R, and it is 
maximal in the medulla, the site most sensitive to I/R injury. By 
comparison, the receptors for IL-34, c-FMS and PTP-ζ, are max-
imally expressed in the chronic phase after I/R. Intrarenal IL-34 
promotes Mø-mediated TEC destruction during the acute and, 
subsequently, the chronic phase after ischemic injury. Intrarenal 
IL-34 fosters Mø accumulation via 2 distinct mechanisms: enhanc-
ing Mø proliferation locally in the kidney and releasing IL-34 into 
the circulation, leading to a rise in BM myeloid cell proliferation 
that subsequently enter the circulation and increase circulating 
monocytes. The IL-34–dependent rise in circulating myeloid cells 
provides a larger pool of myeloid cells available for recruitment to 
the inflamed kidney. IL-34 does not directly recruit monocytes, 
but rather increases intrarenal inflammation and thereby chemo-
kines that draw circulating myeloid cells to the inflamed kidney. 
the renal interstitium in engrafted compared with donor kidneys 
that are even more pronounced during kidney transplant rejec-
tion (Supplemental Figure 6). Note, Mø are far more abundant (2 
times) than neutrophils in the transplanted kidneys. Thus, ische-
mic injury in human kidneys upregulates IL-34 in TECs and simul-
taneously increases renal interstitial Mø and neutrophils. Accom-
panying IL-34 expression by TECs, we detected a pronounced rise 
in serum IL-34 during rejection compared with engraftment and 
healthy controls (Figure 11B). IL-34 serum levels reflected intrare-
nal IL-34 expression, as serum and TEC-derived IL-34 correlate 
with the magnitude of IL-34 expression in rejected and engrafted 
kidney transplants (Figure 11C).
To further explore the relationship of I/R and IL-34 in patients, 
we compared deceased donor kidney (more ischemic) with living 
donor kidneys (less ischemic) prior to and after reperfusion (Sup-
plemental Table 1B). IL-34 expression is higher in human deceased 
and living donor kidneys after reperfusion compared with before 
reperfusion (Figure 12A). Moreover, IL-34 expression is elevated 
in deceased compared with living donor kidneys both before and 
after reperfusion (Figure 12A). This suggests that intrarenal IL-34 
expression rises with increasing renal ischemia in patients receiv-
ing a kidney transplant.
To determine whether the IL-34 receptors are upregulated 
along with IL-34, we probed for PTP-ζ and c-FMS expression in the 
same human kidney transplants (Figure 11A). PTP-ζ and c-FMS 
expression are both upregulated in kidney transplants (Figure 
11A). Moreover, PTP-ζ and c-FMS are expressed by TECs and in 
some cells in the interstitium (Figure 11A). As PTP-ζ is more abun-
Figure 9. IL-34 recruits BM derived cells to the kidney by indirectly amplifying intrarenal chemokines after I/R. (A) Il34–/– and WT mice are intravenously 
injected either with the same or half the number of BM cells from MacGreen mice 3 hours before sacrifice at d1 after I/R. Blood and kidney are collected 
and analyzed by flow cytometry for the number and frequency of donor cells, respectively (n = 5–14/group). (B) Induction of BMMø migration to stimulated 
TEC supernatants incubated with and without diluted anti–IL-34 and anti–MCP-1 Abs (n = 4/group), repeated 3×. Statistical differences are determined by 
Mann-Whitney U test. *P < 0.05, **P < 0.01. Values are means ± SEM.
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after I/R. PTP-ζ and c-FMS may be central to fibrosis, as these 
transcripts rise along with the loss of tubules and replacement by 
fibrosis. Moreover, IL-34 and CSF-1 are overexpressed in chronic 
hepatitis C liver fibrosis and induce profibrotic Mø (39). Dissect-
ing the role of PTP-ζ in kidney disease may be complex, as this 
receptor binds to and signals through the actions of multiple lig-
ands (40), including the heparin binding growth factors pleiot-
rophin and midkine (41), the cell surface protein contactin (42), 
and the extracellular matrix protein tenascin-R (43). It will be 
intriguing to pinpoint the PTP-ζ– and/or c-FMS–mediated IL-34–
dependent and –independent mechanisms that may be central to 
intrarenal fibrosis.
IL-34 and CSF-1 are the principle molecules released from 
TECs that mediate intrarenal Mø proliferation, as eliminating 
both of these molecules, but not either alone, reduces Mø prolifer-
ation to baseline levels. Moreover, CSF-1 does not compensate for 
the lack of IL-34 during inflammation, as ischemia-incited renal 
injury is diminished in Il34–/– compared with WT mice, and stim-
ulated Il34–/– and WT TEC express similar levels of CSF-1. This is 
consistent with the absence of a compensatory increase in Il34 
mRNA expression in Csf1op/op mice in several noninflamed tissues 
(ear, skeletal muscle, liver, salivary gland, and spleen) (15). More-
over, elevated intrarenal IL-34 is not restricted to I/R injury. IL-34 
protein and transcripts are abundantly upregulated in MRL-Faslpr 
mice with spontaneous CKD (lupus nephritis, unpublished data), 
and intrarenal Il34 transcripts are elevated in the kidney of other 
models with lupus nephritis (44). These findings have seeded 
studies to clarify whether IL-34 is a potential therapeutic target for 
chronic kidney diseases with multiple etiologies.
I/R injury is an inevitable consequence of the kidney transplanta-
tion procedure. We detected increased IL-34 expression by TECs 
in human transplanted kidneys. Moreover, IL-34 is increased in 
the serum of recipients with transplanted kidneys and rises higher 
with advancing renal inflammation. CSF-1 does not compensate 
for the absence of IL-34. Thus, targeting IL-34 is a potential ther-
apeutic to suppress AKI and subsequent CKD. Further detailed 
studies are required to determine whether targeting IL-34 during 
the chronic phase after I/R alone suppresses CKD.
While IL-34 and CSF-1 share a common receptor and par-
tially overlap in functions, the list of their distinct actions is rap-
idly expanding (34-37). The roles of IL-34 and CSF-1 clearly differ 
during growth and development. For example, Csf1op/op mice lack-
ing a functional CSF-1 express an obvious phenotype, including 
reduced body and kidney size and weight, frailty, defective skel-
etal and tooth formation, and infertility (24, 38). By comparison, 
other than the microscopically evident loss of Langerhans cells 
and microglia (18, 29), Il34–/– mice express a normal phenotype, 
including normal body and kidney size and weight, and similar 
numbers of circulating and intrarenal monocytes and neutrophils 
compared with WT mice. The recent discovery of a second IL-34 
receptor, PTP-ζ, in neural progenitor and glial cells in the brain 
may be responsible for some differing functions of IL-34 and 
CSF-1. Intrarenal PTP-ζ is expressed primarily by TEC and binds 
to IL-34. Moreover, PTP-ζ is more robustly expressed during 
the chronic compared with acute phase after ischemia-incited 
renal injury. By comparison, intrarenal c-FMS expression is more 
abundant than PTP-ζ during the acute phase, while both IL-34 
receptors are maximally expressed during the chronic phase 
Figure 10. IL-34 mediates a 
rise in intrarenal chemokines 
that recruit monocytes to the 
inflamed kidney. (A) Kidneys are 
analyzed for transcript expres-
sion of selected chemokines at 
d3 after I/R using qPCR (n = 4–5/
group). (B) TECs after stimulation 
with IL-34 and TNFα are analyzed 
for transcript expression of 
select chemokines (n = 4/group), 
repeated 2×. (C) Recruitment 
of myeloid cells tested as in A. 
To inhibit G-coupled receptors, 
donor cells are pretreated with 
PTx (100 ng/ml, 1 hour). Control: 
donor cells pretreated with 
heat-inactivated PTx (n = 5–6/
group). Statistical differences are 
determined by Mann-Whitney 
U test. *P < 0.05, **P < 0.01. 
Values are means ± SEM.
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that recruit monocytes into the inflamed kidney (47). This is con-
sistent with markedly weak IL-34–mediated direct migration of 
the mouse monocyte/Mø cell line (J774A.1) in vitro (17). Moreover, 
IL-34–dependent elevated intrarenal inflammation is a plausible 
explanation for the rise in neutrophils in the circulation and kid-
ney in WT compared with Il34–/– mice (48). Taken together, IL-34 
directly and indirectly mediates AKI, worsening subsequent CKD.
IL-34 fosters homeostatic, protective, tissue-resident Mø in 
select tissues. Mø are divided according to their origin. Tissue- 
resident Mø (Ly6C–) are seeded during early development; are 
maintained locally through homeostatic proliferation, indepen-
dent of monocytes; patrol peripheral tissues; and exert a broad 
range of immunoregulatory, cyto-protective functions (28). By 
comparison, monocyte-derived Mø (Ly6C+) are recruited into 
inflamed tissues, where they multiply and exert cyto-destructive or 
cyto-protective functions (28). Initial in vitro evidence suggested 
that IL-34 promotes the expansion of cyto-protective Mø in tissues, 
as IL-34–stimulated Mø express an immunosuppressive cytokine 
Are the actions of IL-34 and CSF-1 similar or distinct in ische-
mia-incited renal injury? While ischemia-induced IL-34 drives AKI 
and thereby worsens subsequent CKD, our prior studies (4) and 
others (24, 25) indicate that CSF-1 hastens AKI repair after I/R. 
However, CSF-1 mediates repair in AKI and conversely escalates 
spontaneous (MRL-Faslpr lupus nephritis) (3, 5, 7, 8, 20) and induced 
(unilateral ureteral obstruction) (22, 23) CKD. This divergent role of 
CSF-1 is analogous to epidermal growth-factor receptor signaling in 
AKI and CKD. (45, 46). One caveat concerning the distinct actions 
of IL-34 and CSF-1 in AKI relates to comparing differing models/
methods (CSF-1–transgenic, CSF-1–injected, and CSF-1–deficient 
osteopetrotic Csf1op/op mice, versus Il34–/– mice) and experimental 
I/R protocols. Nevertheless, our data support the concept that the 
roles of IL-34 and CSF-1 are dissimilar in renal injury, a finding con-
sistent with nonredundant features of these c-FMS ligands.
Unlike CSF-1, IL-34 does not directly recruit monocytes into the 
inflamed kidney (7). Our data suggest that intrarenal IL-34 incites 
inflammation and the expression of chemokines, such as MCP-1, 
Figure 11. Intrarenal IL-34 is increased in engrafted and rejected kidney transplants. (A) Kidney biopsies include: the *donor (defined as donor biopsy 
from living and deceased donors after reperfusion) and engrafted and rejected (acute cellular) transplant (within 6 months of transplant). IL-34, PTP-ζ, and 
c-FMS expression detected in renal biopsy by immunostaining (brown reaction product) in TECs and interstitium. White arrows denote PTP-ζ–expressing 
cells, and black arrows denote c-FMS–expressing cells. Representative photomicrographs. Original magnification, ×40 (n = 7–12/group). (B) Serum IL-34 
expression in *donor and transplanted kidneys quantified by an ELISA (n = 17–84/group). (C) Correlation of serum and IL-34+ TEC expression (n = 7–10/
group). Demographic and patient clinical characteristics detailed in Supplemental Table 1. Statistics analyzed by the Mann-Whitney U test. *P < 0.05,  
**P < 0.01, ***P < 0.001. Values are means ± SEM.
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increases intrarenal Mø but does not skew the Mø phenotype 
(within the context of the M1 and M2 markers we explored) during 
AKI and subsequent CKD.
We wish to highlight the finding that IL-34 and IL-34 receptors 
are upregulated in ischemia-incited human inflamed kidneys. As 
IL-34 and IL-34–receptor expression in mouse and human kidneys 
are similarly upregulated, we speculate that IL-34 in transplanted 
kidneys may mediate rejection and other forms of renal injury. In 
conclusion, our mouse experimental data and human data suggest 
that targeting IL-34 in the kidney and circulation is likely a poten-
tial therapeutic strategy to suppress AKI and subsequent CKD.
Methods
Mice. We purchased C57Bl/6 (B6) mice from The Jackson Laboratory 
and Harlan. Transgenic Tg(Fms-EGFP) mice that express eGFP under 
the control of Fms promoter and first intron (MacGreen), were pro-
vided by D. Hume (Roslin Institute, University of Edinburgh, Edin-
burgh, United Kingdom). We backcrossed MacGreen mice onto the 
B6 background (MacGreen;B6) (4, 23). To generate IL-34 null LacZ+ 
(Il34–/–;B6) mice, B6 mice were deleted of Il34 exons 3–5 and inter-
crossed with Il34LacZ/+ offspring, as previously described (18). Trans-
genic mice expressing lacZ under the control of Csf1 promoter and the 
first intron (TgN9[Csf1-Z]Ers7/+) (58) were provided by E.R. Stanley 
(Albert Einstein College of Medicine, New York, New York, USA) and 
backcrossed to B6 in our facility at Harvard Medical School, Boston, 
Massachusetts, USA. IL-34 is required for the development of Langer-
hans cells (18); thus, in addition to using PCR to detect the deletion of 
Il34, we probed for the loss of Langerhans cells in the epidermis of the 
ear (59). All breeding housing and colony housing was done at Har-
vard Medical School.
I/R. We anesthetized female mice (6 weeks of age) and exposed 
the left kidney through a flank incision. We induced ischemia by 
clamping the renal pedicle with nontraumatic microaneurysm clamps 
(Roboz Surgical Instrument Co.). Clamps were removed after 45 min-
utes. Body temperature was controlled at 36.8°C–37.2°C throughout 
the procedure.
In situ hybridization. The digoxigenin-labeled (DIG-labeled) anti-
sense oligonucleotide probe for mouse IL-34 was synthesized by in 
vitro transcription using T7 RNA polymerase and Dig Labeling Mix 
(Roche Applied Science) from cDNA template amplified from plasmid 
IL-34–pBS-SK (a gift from E.R. Stanley), and purified with Micro Bio-
profile (IL-10hi, IL-12lo), reduce Mø mediated T cell stimulation and 
proliferation, and skew human monocytes toward a M2 phenotype 
(49). Moreover, IL-34 is required for the maintenance of homeo-
static cyto-protective tissue-resident Mø (Ly6C–) in brain and skin 
(18, 29). We now report that IL-34 does not maintain kidney-resi-
dent Mø, as the number and frequency of Ly6C– is similar in non-
manipulated Il34–/– and WT kidneys. Thus, IL-34 is not required to 
maintain homeostatic cyto-protective Mø in the resting kidney.
IL-34 mediates intrarenal Mø accumulation but does not shift 
phenotypes during AKI and subsequent CKD. Several previous 
studies indicate that M1-like Mø drive injury and M2-like Mø medi-
ate repair during renal inflammation (1, 3, 25). Our findings are 
consistent with a rise in IL-34–dependent M1-like Mø mediating 
more severe AKI. Although the abundance of M2-like Mø in ische-
mia-incited CKD is seemingly at odds with some prior studies in 
renal inflammation, there are possible explanations. Growing evi-
dence shows M2-like Mø are the dominant phenotype in fibrotic 
lesions of CKD of many etiologies. For example, the abundance 
of M2-like Mø in human and mouse polycystic kidney disease 
(PKD), contribute to the progression of renal disease by promoting 
cyst growth and fibrosis (50). Similarly, M2-like Mø proliferation 
and infiltration is associated with tubular injury and progression 
of fibrosis during inflammation in human kidney transplant allo-
grafts (51, 52). Moreover, insufficient renal epithelial healing in 
mice promotes an expansion of M2-like Mø that accelerates fibro-
genesis (reviewed in ref. 53). These findings in kidney disease are 
in keeping with the profibrotic functions of M2-like Mø in the liver 
(54). As we find a predominance of M2-like Mø–expressing mark-
ers (CD 206+, Arginase-1+, Dectin-1+) linked to fibrosis (55–57) 
in fibrotic kidneys after I/R, our findings are consistent with the 
concept that these intrarenal Mø are profibrotic. Since fibrosis is a 
protective response to tissue injury, M2-like Mø may mediate both 
repair and fibrosis. Moreover, when renal injury is severe, as in our 
study, fibrosis results in substantial loss of tissue and CKD. Thus, 
it is not inconsistent that some have found intrarenal M2-like Mø 
during renal repair, while we found M2-like Mø in fibrotic kid-
neys during CKD. To add to the complexity of defining the roles 
of M2-like Mø, activated Mø phenotypes extend far beyond the 
simplistic M1 and M2 paradigm, making it challenging to compare 
Mø phenotypes and functions in differing experimental settings, 
even within the kidney. In conclusion, our findings show IL-34 
Figure 12. IL-34 is upregulated in reperfused deceased donor kidneys, and PTP-ζ is more abundantly expressed in chronic than acute transplant rejected 
kidneys. (A) IL-34 expression in living and deceased donor biopsies before and after reperfusion (n = 7/group). (B) PTP-ζ expression in acute and chronic 
disease in human kidney transplants (n = 7/group). Graph and representative photomicrographs. Original magnification, ×40. Demographic and patient 
clinical characteristics detailed in Supplemental Table 1. Statistics analyzed by the Mann-Whitney U test. *P < 0.05. Values are means ± SEM.
Downloaded from http://www.jci.org on December 11, 2015.   http://dx.doi.org/10.1172/JCI81166
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
3 2 1 1jci.org   Volume 125   Number 8   August 2015
goat anti-mouse Ab, followed by development with 3-3-diaminoben-
zidine (Vector Laboratories), as previously detailed (4). Nonspecific 
binding was determined using rabbit anti-human IgG (IL-34 staining) 
or rat anti-human (Ly6G staining), or with mouse anti-human IgG 
(CD68 staining) (eBioscience). We determined the percent-positive 
TECs or positive infiltrating cells in 10 randomly selected HPFs.
Albuminuria. To quantify albuminuria levels, we analyzed 20 μl 
urine collected over 8 hours by SDS-PAGE, as previously described (64).
Collagen detection. We stained paraffin sections after rehydration 
in Picrosirius red solution for 1 hour and rinsed with acidified water. 
After kidney sections were dehydrated and mounted, the magnitude of 
staining was analyzed as previously detailed (4) using a Nikon Eclipse 
E1000 upright fluorescence microscope and Adobe Photoshop CS2.
KIM-1 and NGAL expression. Kidney cryostat-cut sections were 
stained with polyclonal anti–KIM-1 Ab to determine tubular injury, as 
previously detailed (4). The NGAL protein was detected using a Lumi-
nex xMAP technology, as previously described (65).
Generating BMMø. Mø were generated from mouse BM, as pre-
viously detailed (3).
Stimulating Mø using hypoxic TEC supernatant. We isolated and 
expanded TECs from Il34–/– and WT kidneys, as previously reported 
(3). We cultured TECs for 24 hours under hypoxic conditions with 99% 
N2/1% O2 at 37°C in a hypoxic chamber and evaluated viability using 
both microscopic analysis of trypan blue exclusion staining and flow 
cytometry analysis of PI staining. Cell supernatant was collected after 
hypoxia and was used to stimulate BMMø. To derive BMMø, we cul-
tured BM in L929 conditioned media and then starved BMMø in serum-
free DMEM medium without L929 for 2 hours. We incubated BMMø 
with supernatant from hypoxic Il34–/– and WT TECs. To restore IL-34 
in Il34–/– TEC supernatants, we added rIL-34 protein to hypoxic Il34–/– 
TEC supernatant at concentrations ranging from 50–500 ng/mL. To 
block IL-34 and CSF-1, anti–IL-34 Ab (10 μg/ml, catalog AF5195, R&D 
Systems) and anti–CSF-1 Abs (2 μg/ml, 552513, BD Biosciences) neu-
tralizing Abs were added to hypoxic WT and Il34–/– TEC supernatants 
during incubation with BMMø. After incubating for 24 hours, we ana-
lyzed Mø proliferation with the MTT assay (Roche Diagnostics) and 
BrdU incorporation (10 μM, 2 hours) using flow cytometry.
ELISA. To quantify IL-34 and CSF-1 levels, in the kidney, circu-
lation and hypoxic and normoxic TEC supernatants, samples were 
analyzed using a mouse IL-34 ELISA (R&D Systems) according to the 
manufacturer’s instructions and a mouse CSF-1 ELISA (7). We mea-
sured human IL-34 levels with a human IL-34 ELISA (R&D Systems) 
according to the manufacturer’s instructions. All measurements were 
made in duplicate.
qPCR. qPCR was performed, as previously described (4). We 
detected Csf1, Il34, Fms, Ptprz1 and Gapdh using QuantiTect Primer 
Assays (QIAGEN) or using primers purchased from Invitrogen and 
Integrated DNA Technologies: Csf1, forward 5′-GGCTTGGCTTGG-
GATGATTCT-3′, reverse 5′-GAGGGTCTGGCAGGTACTC-3′; Il34, 
forward 5′-TTGCTGTAAACAAAGCCCCAT-3′, reverse 5′-CCGAGA-
CAAAGGGTACACATTT-3′; Fms, forward 5′-TGTCATCGAGCCTAGT-
GGC-3′, reverse 5′-CGGGAgATTCAGGGTCCAAg-3′; and Gapdh, 
forward 5′-AGGTCGGTGTGAACGGATTTG-3′, reverse 5′-TGTAGAC-
CATGTAGTTGAGGTCA-3′. Other purchased primers used in this 
study were: collagen I, forward 5′-TgACTGGAAGAGCGGAGAGT-3′, 
reverse 5′-GTTCGGCTGATGTACCAgT-3′; fractalkine/Cx3cl1, for-
ward 5′-TCGGACTTTGTTGGTTCCTC-3′, reverse 5′-CAAAATGG-
Spin 30 Columns (Bio-Rad). Kidneys were fixed in 4% paraformalde-
hyde overnight, immersed in 30% sucrose/PBS overnight at 4°C, and 
then embedded and cryostat-sectioned at 20 μm. The kidney sections 
were prepared and processed for in situ hybridization, as previously 
described (60). After development, slides were fixed in 4% PFA over-
night and dried, and cover slips were mounted for imaging.
β-Galactosidase. β-Galactosidase staining was performed, as pre-
viously described (61). Kidneys were fixed in 4% paraformaldehyde 
for 3 hours at 4°C, embedded and sectioned at 20-μm thick sections. 
Cryosections were stained with X-gal (catalog X4281C10; Gold Bio-
technology) overnight at 37°C and subsequently counterstained with 
Nuclear Fast Red (catalog N3020; Sigma-Aldrich).
Immunoblotting. Kidney tissues were homogenized in RIPA buf-
fer, and 25 μg total protein was used for immunoblotting, as previously 
described (62). Blots were probed with mouse monoclonal PTP-ζ Ab 
(3F8; Developmental Studies Hybridoma Bank, University of Iowa, 
Iowa City, Iowa, USA). Mouse monoclonal anti-GAPDH Ab (cata-
log D16H11; Cell Signaling Technology) was used as loading control. 
Images were captured using ChemiDoc MP imaging system (Bio-Rad).
Immunoprecipitation. We performed immunoprecipitation, as pre-
viously described (62). Briefly, kidney tissues were homogenized in 
CHAPS buffer (30 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% CHAPS con-
taining protease and phosphatase inhibitor cocktails [Sigma-Aldrich]) 
and 250 μg total protein incubated with 1 μg of PTP-ζ Ab overnight 
at 4°C. Proteins were transferred onto nitrocellulose membrane, and 
immunoblotting was performed with polyclonal anti-sheep IL-34 Ab 
against Asn21-Pro242 (catalog AF5265; R&D Systems). Mouse mono-
clonal anti-GAPDH, (catalog D16H11; Cell Signaling Technology) and 
mouse heavy chain IgG were used as loading control for input and 
immunoprecipitation, respectively.
Renal histopathology. Kidneys were fixed in 10% neutral buffered 
formalin, embedded in paraffin, sectioned (4 μm), and stained with 
periodic acid-Schiff (PAS). We scored kidney pathology, as previously 
detailed (63).
Immunostaining. We stained cryostat-cut mouse kidney sections 
for the presence of: Mø, using anti–mouse F4/80 Ab (clone BM-8; 
Invitrogen) and anti–mouse CD68 Ab (clone FA-11; AbD Serotec), as 
previously detailed (4); proximal tubules using fluorescein isothio-
cyanate–conjugated (FITC-conjugated) lotus tetragonolobus lectin 
(LTL; Vector Laboratories) and collecting ducts using biotinylated dol-
ichos biflorus agglutinin (DBA; Vector Laboratories) in combination 
with Texas red streptavidin (Vector Laboratories); and neutrophils, 
using anti–mouse Ly6G Ab (clone 1A8, BioLegend). To determine 
the number of proliferating Mø, cryosections were stained with anti–
mouse F4/80 Ab (clone BM-8, Invitrogen), and anti–mouse Ki-67 Ab 
(clone SP6, Vector Laboratories), followed by FITC-conjugated goat 
anti-rat IgG Ab (Invitrogen) and Cy3-conjugated goat anti-rabbit IgG 
Ab (Invitrogen). We enumerated the number of F4/80+/Ki-67+ cells in 
20 high-power fields (HPF).
Kidney biopsy sections were incubated with a primary Ab, rabbit 
anti–human IL-34 Ab (clone C-19, catalog sc-243072, Santa Cruz Bio-
technology Inc.) rabbit anti–human PTP-ζ (catalog ab126497, Abcam), 
rabbit anti–human CSF-1R (clone C-20, catalog sc-692, Santa Cruz 
Biotechnology Inc.), rat anti–human Ly6G (clone RB6-8C5, catalog 
ab25377, Abcam), and mouse anti–human CD68 (clone SPM130, 
sc-52998, Santa Cruz Biotechnology Inc.). The primary Ab was detected 
by incubating with biotinylated goat anti-rabbit Ab, rabbit anti-rat, and 
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Serum and renal biopsy specimens. The demographic and clinical 
characteristics for the cohort used in this study are listed in Supple-
mental Table 1, A and B. Human kidney sections from transplanted 
kidney biopsies and donor biopsies prior to transplantation were pro-
vided by the Department of Pathology, Friedrich-Alexander Univer-
sity of Erlangen-Nuernberg, Erlangen, Germany. Donor-kidney biop-
sies from living and deceased donors were evaluated before and after 
reperfusion. The following criteria were used to define these patient 
biopsies: living donors were defined as healthy individuals donating 
their kidney to a family member; deceased donors were defined as 
patients who have complete and irreversible loss of brain function; 
“before reperfusion” was defined as a biopsy after removing the kid-
ney from the donor prior to transplantation; and “after reperfusion” 
was defined as a biopsy after kidney transplantation into the recipient. 
Renal pathologists, without access to the patient’s clinical data, evalu-
ated these biopsies according to the BANFF renal allograft pathology 
classification (67–69). We analyzed serum samples from patients with 
histology-proven diagnosis of cellular rejection or engraftment (no 
rejection). Blood samples were collected, centrifuged, aliquoted, and 
stored at –30°C prior to analysis.
Statistics. Data represent the mean ± SEM prepared using Graph-
Pad Prism software, version 5.0. We used the nonparametric Mann–
Whitney U test to evaluate P values.
Study approval. Use of mice in this study was reviewed and 
approved by the Standing Committee on Animals in the Harvard 
Medical School, in adherence to standards set in the Guide for the Care 
and Use of Laboratory Animals (8th edition, The National Academies 
Press, revised 2011). Specimens for human study analysis were taken 
from patients after informed consent. The use of these specimens 
was approved by the Standing Committee for Clinical Studies of the 
Johannes-Gutenberg University, Mainz, Germany, in adherence to the 
Declaration of Helsinki and analyzed retrospectively.
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CACAGACATTGG-3′; Kim1, forward 5′-TAAACCAGAGATTCCCA-
CAC-3′, reverse 5′-GATCTTGTTGAAATAGTCGTG-3′; Mcp-1/Ccl2, 
forward 5′-GCTTGAGGTGGTTGTGGAAAA-3′, reverse 5′-CTCACCT-
gCTgCTACTCATTC-3′; Mip1a/Ccl3, forward 5′-TCTCCACCACT-
GCCCTTgCT-3′, reverse 5′-GGCGTGGAATCTTCCGGCTGT-3′; and 
Ptprz1, forward 5′-GGAGTATCCAACAGTTCAGAGGC-3′, reverse 
5′-AAGTCAGGGCAGACACGATCAC-3′. Ip10/Cxcl10 expression was 
examined using primers designed by Applied Biosystems. The data were 
analyzed by the ΔΔ-CT method.
Flow cytometry. We prepared and stained single-cell suspensions 
from kidneys, RBC-lysed BM, and blood cells for intracellular and 
extracellular antigens as previously described (63).
Antibodies for flow cytometry. We used the following antibodies 
from BioLegend for FACS analysis: FITC-conjugated anti–mouse/
human CD11b Ab (clone M1/70); phycoerythrin-conjugated (PE-con-
jugated) anti–mouse CD115 Ab (clone AFS98); FITC-conjugated anti–
mouse CD206 Ab (clone 15-2); PE-conjugated anti–mouse Ly6C Ab 
(clone HK1.4); PE-conjugated anti–Dectin-1 Ab (clone RH1); PerCP/
Cy5.5-conjugated anti–mouse/human CD11b Ab (clone M1/70); allo-
phycocyanin-conjugated (APC-conjugated) anti–mouse F4/80 Ab 
(clone BM-8); pacific blue–conjugated anti–mouse CD45 Ab (clone 
30-F11); APC/Cy7-conjugated anti–mouse Ly6G Ab (clone 1A8); bioti-
nylated anti–mouse Ly6C Ab (clone HK1.4); FITC-conjugated TNFα 
(clone MP6-XT22); and FITC-conjugated streptavidin. In addition, 
we used FITC-conjugated anti–CD3ε (clone 145-2C11) Ab from eBio-
science, FITC-conjugated anti–iNOS-2 (6/iNOS/NOS Type II) Ab 
from BD Biosciences, and PE-conjugated anti–Arginase-1 polyclonal 
Ab from R&D Systems.
BrdU incorporation assay. We injected mice (i.p.) with BrdU (2 mg/
mouse, Sigma-Aldrich) 3 hours before sacrifice. BrdU+ cells were ana-
lyzed with an anti-BrdU Ab (clone Bu20a, BioLegend) by flow cytometry.
Adoptive transfer. We isolated BM from MacGreen;B6 mice and 
adoptively transferred the eGFP+ cells (2 × 107 and 1 × 107) by injection 
into the tail vein of Il34–/– and WT mice 24 hours after I/R. Mice were 
sacrificed 3 hours later. Kidney and blood samples were processed to 
detect eGFP+ cells using flow cytometry, as previously detailed (63).
Recruitment assays. BM (2 × 107) cells from MacGreen mice 
(eGFP+ myeloid cells) were stimulated either with active or heat- 
inactivated (95°C, 30 minutes) PTx, as previously described (66), 
and adoptively transferred into WT B6 mice after I/R (d1). After 
3 hours, kidneys and blood were collected and analyzed by flow 
cytometry. The viability of donor cells was tested using PI (Sigma- 
Aldrich) and analyzed by flow cytometry.
Chemotaxis assay. TECs isolated from B6 mice were incubated 
with TNFα (25 ng/ml) with and without anti–IL-34 Ab (catalog AF5195, 
R&D Systems) and anti–MCP-1 Ab (catalog 479-JE-010, R&D Systems) 
using increasing concentrations (1.25–40 μg/ml). Following stimulation 
for 24 hours, the supernatant was replaced and stimulated TECs were 
coincubated with primary isolated Mø from B6 mice using a 2-chamber, 
96-well plate separated by a polycarbonate membrane (pore size: 5 μg/
ml). To quantify Mø chemotaxis, samples were analyzed in duplicate 
according to the manufacturer’s instructions (Cell Biolabs Inc.).
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